Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18112448 | 0.78 | — | — | |
| SCHEMBL16860545 | 0.78 | TRIM24 (0.38) | — | |
| SCHEMBL16860544 | 0.78 | TRIM24 (0.38) | — | |
| SCHEMBL31378988 | 0.76 | — | — | |
| Cyclooctene SCHEMBL8046390 | 0.74 | — | — | |
| Cyclooctene SCHEMBL7121430 | 0.74 | HDAC3 (0.30) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Cyclooctene SCHEMBL5279918 | 0.74 | HDAC3 (0.30) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Cyclooctene SCHEMBL5279923 | 0.74 | HDAC3 (0.30) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10712112 | 0.74 | — | — | |
| Cyclooctene SCHEMBL7121436 | 0.74 | HDAC3 (0.30) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1471567-B1 | Organometallic iridium compounds, processes for producing the same, and processes for producing thin films | TOSOH CORP (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-6884902-B2 | Organometallic iridium compound, process of producing the same, and process of producing thin film | TOSOH CORPORATION (JP) | 2005-04-26 | — | — | US | disclosed |
| US-20040215029-A1 | Novel organometallic iridium compound, process of producing the same, and process of producing thin film | TOSOH CORPORATION | 2004-10-28 | — | — | US | disclosed |
| EP-1471567-A1 | Organometallic iridium compounds, processes for producing the same, and processes for producing thin films | Tosoh Corporation (JP) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040215029-A1 | Novel organometallic iridium compound, process of producing the same, and process of producing thin film | HMGCR, SREBF1, APOB | HDAC3 4474/4885HDAC4 3609/4885HDAC1 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.